Study: CAR T-cell therapy safe and effective in youth with leukemia

February 1, 2018, Children's Hospital Los Angeles
This graphic shows how CAR-T therapy works. Credit: UT Southwestern Medical Center

Results of the global, multicenter, pivotal phase 2 study that led to the first FDA approval of a gene therapy/cell therapy approach known as CAR T-cell therapy, were published today in the New England Journal of Medicine. The therapy, tisagenlecleucel, uses a patient's own white blood cells that have been genetically re-engineered to specifically target and kill cancer cells. It was approved in August 2017 to treat pediatric acute lymphoblastic leukemia (ALL), the most common childhood cancer. Senior authors on the study include Stephan A. Grupp, MD, PhD, of Children's Hospital of Philadelphia and Michael A. Pulsipher, MD, of Children's Hospital Los Angeles (CHLA).

"Stephan Grupp and his team at CHOP pioneered this and were able to show it was effective when manufactured and administered at a single site," said Pulsipher, section head of Blood and Marrow Transplantation at the Children's Center for Cancer and Blood Diseases at CHLA. "For this study, we worked together with many colleagues to demonstrate that with CAR T-cell therapy is not only feasible in a global, multisite setting but that it is also equally safe and effective."

Pulsipher, who is also Chair of the Pediatric Blood and Marrow Transplant Consortium, worked with Grupp and the paper's primary author, Shannon Maude from CHOP, as well as investigators from the US, Canada, Europe, Japan, and Australia to organize and run the trial, teaming with Novartis, the industry sponsor of the trial. The study was conducted at 25 sites in 11 countries.

The New England Journal paper reports on 75 evaluable patients between 3 to 21 years of age with relapsed or treatment refractory B-cell ALL. 61% of these patients had relapsed after allogeneic hematopoietic stem cell transplantation, an intensive therapy intended to be curative and whose failure leaves few remaining options. For comparison, the paper cites another FDA-approved therapy for the treatment of children with relapsed or refractory ALL; it produced a response rate of 20% with a median overall survival time of 13 weeks.

"Previously, for patients who relapsed after transplant or did not respond to treatment - there wasn't much else we had to offer them and often, they went to hospice," said Pulsipher. "Now, instead of sending them to hospice - we treat them with CAR-T-cells, make them better, then send them home."

The updated analysis showed an overall remission rate of 81% within 3 months of treatment. All patients who responded to therapy showed no minimal residual disease by flow cytometry - the most sensitive means of analysis. Overall survival was 90% at 6 months and 76% at 12 months. The median length of remission was not reached, with tisagenlecleucel remaining in the for up to 20 months.

"CAR-T therapy is truly a game changer for pediatric leukemia," said Alan S. Wayne, MD, director of the Children's Center for Cancer and Blood Diseases at CHLA. "We are pleased to be one of a small number of institutions able to offer this new treatment to children for whom conventional therapies have failed."

Substantial side effects are associated with this therapy; grade 3 or 4 adverse events that may have been related to the therapy occurred in 73% of patients. The most significant side effects included cytokine release syndrome, often requiring admission to an intensive care unit, and neurological events in 40% of .

Explore further: Clinical trial suggests new cell therapy for relapsed leukemia patients

Related Stories

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

CAR-T immunotherapy now approved for certain adult lymphoma patients

October 20, 2017
The Food and Drug Administration (FDA) has approved a breakthrough cancer therapy known as CAR-T for use in adults with advanced lymphoma. The therapy uses a patient's own white blood cells, which are modified in a lab and re-trained ...

CAR T cell immunotherapy continues to yield complete responses in leukemia

December 5, 2016
A highly innovative, personalized cell-based treatment for a high-risk form of the most common childhood cancer continues to move through clinical trials. Pediatric oncologists from Children's Hospital of Philadelphia (CHOP) ...

Landmark CAR-T cancer study published

December 10, 2017
Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.

Phase 2 CAR-T study reports significant remission rates at 15-month follow up

December 10, 2017
A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with aggressive large B-cell lymphoma remained in remission at 15 months following treatment ...

Immune therapy induces remission for many with ALL

October 16, 2014
(HealthDay)—An experimental immune-system therapy can often lead to complete remission in advanced acute lymphoblastic leukemia (ALL) patients who have run out of other options, according to research published in the Oct. ...

Recommended for you

New 'SLICE' tool can massively expand immune system's cancer-fighting repertoire

November 15, 2018
Immunotherapy can cure some cancers that until fairly recently were considered fatal. In addition to developing drugs that boost the immune system's cancer-fighting abilities, scientists are becoming expert at manipulating ...

Anti-malaria drugs have shown promise in treating cancer, and now researchers know why

November 15, 2018
Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers from the Abramson ...

Researchers identify a mechanism that fuels cancer cells' growth

November 14, 2018
Scientists at the UCLA Jonsson Comprehensive Cancer Center have identified sodium glucose transporter 2, or SGLT2, as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes ...

A new approach to detecting cancer earlier from blood tests: study

November 14, 2018
Cancer scientists led by principal investigator Dr. Daniel De Carvalho at Princess Margaret Cancer Centre have combined "liquid biopsy", epigenetic alterations and machine learning to develop a blood test to detect and classify ...

New antibody breakthrough to lead the fight against cancer

November 14, 2018
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defence against the body's immune system.

Photoacoustic imaging may help doctors detect ovarian tumors earlier

November 14, 2018
Ovarian cancer claims the lives of more than 14,000 in the U.S. each year, ranking fifth among cancer deaths in women. A multidisciplinary team at Washington University in St. Louis has found an innovative way to use sound ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.